- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 5/027 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link in which at least a gamma-amino acid is involved, e.g. statine
Patent holdings for IPC class C07K 5/027
Total number of patents in this class: 94
10-year publication summary
|
4
|
6
|
11
|
10
|
7
|
4
|
4
|
5
|
8
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Zymeworks Inc. | 256 |
7 |
| SeaGen Inc | 531 |
4 |
| Ontario Institute for Cancer Research (oicr) | 86 |
3 |
| Pfizer Inc. | 3409 |
2 |
| Toray Industries, Inc. | 7139 |
2 |
| Exelixis, Inc. | 394 |
2 |
| Regeneron Pharmaceuticals, Inc. | 4786 |
2 |
| Ariel Scientific Innovations Ltd | 251 |
2 |
| Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. | 24 |
2 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 87 |
2 |
| Levena Biopharma Co., Ltd. | 9 |
2 |
| Ganzhou Hemay Pharmaceutical, Co., Ltd | 21 |
2 |
| Mabplex International Co., Ltd. | 18 |
2 |
| Hangzhou Adcoris Biopharma Co., Ltd. | 36 |
2 |
| Hainan Simcere Pharmaceutical Co., Ltd. | 19 |
2 |
| Fujian Akeylink Biotechnology Co., Ltd. | 36 |
2 |
| Surio Therapeutics Co., Ltd | 7 |
2 |
| Novartis AG | 10173 |
1 |
| Genentech, Inc. | 4114 |
1 |
| Centre National de La Recherche Scientifique | 11059 |
1 |
| Other owners | 49 |